IBS symptoms in IBD remission: A dietitian's guide

IBS-type symptoms in IBD remission are functional gut symptoms, most often abdominal pain, bloating, and altered bowel habits, that persist despite confirmed absence of inflammation, affecting around one in three patients with IBD in remission.¹

For the dietitian, this is the cohort where the pressure to restrict often comes from an anxious patient rather than from the clinical picture. They're back in clinic, symptomatic, certain something they're eating is to blame, and asking for the next elimination diet. The instinct they arrive with is to cut more foods. The more useful move is to slow down and work out what these symptoms actually are, because on a healed mucosa they are rarely a food problem in the way the patient thinks.

That reframe is the whole job here. Persistent symptoms in confirmed remission are largely driven by visceral hypersensitivity and altered gut-brain signaling, not by ongoing inflammation or by the foods being blamed for them.² Treat them as an inflammatory problem and you escalate medication that won't help. Read them as a simple intolerance and you narrow the diet of someone already carrying nutritional risk, often without easing the symptom. This guide walks through separating the two, ruling out the mimics, and knowing when dietary therapy is the wrong tool.

Is it a flare or IBS? How to tell the difference

Persistent symptoms in IBD are not proof of a flare, and nothing in the nutrition plan should change until inflammation is ruled in or out objectively. Fecal calprotectin is the first-line check: a result below 150 µg/g on a symptomatic patient points away from active disease and toward a functional cause, while a raised result sends them back to the gastroenterologist before any diet conversation.²

The distinction matters because the two states call for opposite responses. Active inflammation is a medication conversation. Symptoms on a healed mucosa are a gut-brain and food-relationship conversation, and treating the second as though it were the first is how patients cycle through exclusion diets that were never going to work. This is also why symptom-defined remission overstates the problem: the one-in-three figure falls to roughly one in four when remission is confirmed endoscopically rather than by symptoms alone.¹

One caveat worth holding: calprotectin is less reliable in isolated small bowel Crohn's disease, where it can read normal despite active disease. If the clinical picture doesn't fit the number, imaging settles it before you attribute anything to a functional cause.²

What else could it be? Mimics to rule out in IBD

Before you attribute symptoms to a functional overlay, rule out the conditions that imitate it, because several respond to targeted management rather than broad restriction. A normal calprotectin tells you it isn't inflammation; it doesn't tell you it's IBS.

Disordered eating is the row to slow down on, because the risk shifts with disease phase rather than disappearing at remission. Weight regain after a flare is a common trigger for body-image-driven restriction, so screening should be ongoing, not a one-time check at diagnosis.

"Screening should be ongoing because, in my experience, many patients with IBD are focused on regaining weight when they've lost weight and have active IBD, but when they go into remission and start regaining weight, body image-driven disordered eating can show up."
– Brittany Rogers, registered dietitian, founder of Roman Well

Watch: Rethinking nutrition in IBS and IBD

Nutrition in IBS and IBD is as misunderstood as it is talked about, and this webinar moves the focus from restriction toward practical, sustainable outcomes. Morgan Binder, PA-C, RDN, a physician assistant and registered dietitian at Arizona Digestive Health, shares her integrated, whole-person approach to IBS and IBD care, including diet strategies for IBD in remission and how they differ from managing an active flare.

Gut-directed hypnotherapy for IBS symptoms in IBD

Once inflammation is excluded and the mimics are managed, the symptoms left over are largely maintained by visceral hypersensitivity and altered gut-brain signaling, which no exclusion diet modifies.³ This is the point to add a gut-brain approach rather than subtract more foods, and the IBD-specific evidence now supports it: gut-directed hypnotherapy prolonged clinical remission in quiescent ulcerative colitis in a randomized trial.⁵

Low FODMAP still has a role, but a bounded one. In a randomized trial in confirmed IBD remission, four weeks of low FODMAP advice:

• improved individual symptom scores and the proportion reporting adequate relief³

• did not significantly change overall IBS symptom severity versus sham advice³

• reduced beneficial Bifidobacterium longum, B. adolescentis, and Faecalibacterium prausnitzii³

So the ceiling is real and the cost is measurable, which is exactly why an open-ended restriction phase is a poor default in a group already carrying nutritional and psychological risk. Set the reintroduction date when the restriction starts, and pair it with something that targets the mechanism the diet doesn't reach.

Trigger type doesn't seem to change the response. In a Nerva analysis of 26,008 users presented at Australian Gastroenterology Week in 2026, patients whose primary symptoms were food-related and those whose symptoms were stress-related showed no difference in adherence or clinical response to the gut-brain therapy program.⁴ In practice, that means the food-triggered patient is as reasonable a candidate for gut-brain therapy as the stress-triggered one.

That mechanism is where a structured gut-brain therapy program fits. Nerva is a digital gut-brain therapy program, 6 weeks, 15–20 minutes a day, combining gut-directed hypnotherapy, cognitive behavioral education, and breathing techniques. It works alongside dietary and medical care rather than replacing either, and a trial with Monash University researchers is currently evaluating it in patients with quiescent IBD and IBS-like symptoms. Framed to the patient, it gives them something active to do that isn't another food to fear.

"The combined efforts of not only the gastroenterologist, the dietitian, and the GI therapist can allow a patient to really feel completely heard and seen, as well as giving them that sense of having a team that really is dedicated to their care."
– Nancee Jaffe, GI expert registered dietitian, UCLA Vatche and Tamar Manoukian Division of Digestive Diseases

Before your next remission patient: save the gut-brain referral form

The next patient who's in remission but still symptomatic will come around again. Bookmark the referral form so the gut-brain step is one click away when you reach it, not a task for later.

Frequently asked questions

How do you tell the difference between an IBD flare and IBS?

Fecal calprotectin is the fastest way to separate the two: a result below 150 µg/g on a symptomatic patient points to a functional cause rather than active inflammation. A raised result warrants gastroenterology review before any dietary change.²

Can you have IBS and IBD at the same time?

IBS-type symptoms and IBD frequently coexist, affecting around a third of patients whose IBD is in remission.¹ The symptoms are genuine but functional, meaning they arise from gut-brain signaling rather than from the inflammatory disease itself.

Is the low FODMAP diet safe for IBD?

A low FODMAP diet can ease functional symptoms in quiescent IBD over a short restriction phase, but it lowers beneficial gut bacteria and is not intended as a long-term pattern.³ A structured reintroduction phase and dietitian oversight keep the diet as broad as possible.

Does gut-directed hypnotherapy work for IBD patients?

Gut-directed hypnotherapy has prolonged clinical remission in quiescent ulcerative colitis and is used for the functional symptoms that persist after inflammation is controlled.⁵ It targets visceral hypersensitivity, the mechanism that dietary change does not address.

Should a dietitian refer gut-brain therapy?

Gut-brain therapy suits patients whose symptoms persist despite confirmed remission and appropriate dietary management, particularly where food-related anxiety is driving restriction. Digital programs have widened access where GI-specialized psychology services are scarce.

References

1. Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1053-1062. doi:10.1016/S2468-1253(20)30300-9

2. Singh S, Ananthakrishnan AN, Nguyen NH, et al. AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis. Gastroenterology. 2023;164(3):344-372. doi:10.1053/j.gastro.2022.12.007

3. Cox SR, Lindsay JO, Fromentin S, et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology. 2020;158(1):176-188.e7. doi:10.1053/j.gastro.2019.09.024

4. Dabash O, Hall C, Peters SL, Raik-Allen S. No difference in adherence or clinical response to a digital brain-gut behavioural therapy program among 26,008 users reporting food-related or stress-related primary symptom triggers. Abstract presented at: Australian Gastroenterology Week 2026; August 28–31, 2026; Perth, Australia.

5. Keefer L, Taft TH, Kiebles JL, Martinovich Z, Barrett TA, Palsson OS. Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. Aliment Pharmacol Ther. 2013;38(7):761-771. doi:10.1111/apt.12449